Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02331498 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Study acronym: PAZOGLIO
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v14
  2. Re-verified, no change to tracked fieldsv13
  3. Primary completion date: Aug 2025 to Feb 2027v12
  4. Re-verified, no change to tracked fieldsv11
  5. Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Aug 2023 to Aug 2025
    • Study completion date: Aug 2025 to Aug 2030
    • Site details revised
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary completion date: Aug 2022 to Aug 2023
    • Study completion date: Aug 2023 to Aug 2025
    v9
  2. Primary completion date: Jan 2021 to Aug 2022
    • Study completion date: Aug 2021 to Aug 2023
    v8
  3. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Aug 2020 to Jan 2021
    • Study completion date: Mar 2021 to Aug 2021
    • Site details revised
    v7
  4. Primary completion date: Aug 2018 to Aug 2020
    • Study completion date: Dec 2018 to Mar 2021
    v6
  5. Re-verified, no change to tracked fieldsv5
  6. Primary completion date: Aug 2017 to Aug 2018
    • Study completion date: Dec 2017 to Dec 2018
    v4
  7. Re-verified, no change to tracked fieldsv3
  8. Start date: Nov 2014 to Jun 2015v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Centre Antoine Lacassagne
46 trials monitored
See 1 trial at risk
Glioma
1,251 trials monitored
See 88 trials at risk
Glioblastoma
710 trials monitored
See 52 trials at risk
A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)
Trial Details
NCT Number NCT02331498
Lead Sponsor Centre Antoine Lacassagne
Collaborators: GlaxoSmithKline
Conditions
(from sponsor)		 Glioblastoma Multiforme
Related terms Glioblastoma
Enrollment 51 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov